2024
High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement and Outcomes in a Multi-Institutional Series
Epperla N, Zayac A, Landsburg D, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Bond D, Evens A, Naik S, Kamdar M, Haverkos B, Karmali R, Farooq U, Vose J, Rubinstein P, Chaudhry A, Olszewski A. High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement and Outcomes in a Multi-Institutional Series. Blood Advances 2024 PMID: 39189932, DOI: 10.1182/bloodadvances.2024013791.Peer-Reviewed Original ResearchBaseline CNS involvementCentral nervous system recurrenceHigh-grade B-cell lymphomaCentral nervous systemB-cell lymphomaCNS involvementCNS recurrenceIncidence of CNS recurrenceRisk of CNS recurrenceCentral nervous system involvementMulti-institutional seriesNon-GCB subtypeBone marrow involvementMulticenter retrospective studyCNS-IPIRisk factor analysisMarrow involvementMYC rearrangementNon-GCBPrimary therapyCD5 expressionAutologous transplantationSurvival outcomesNo significant differenceNOS patients
2019
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. Journal Of Clinical Oncology 2019, 37: 471-480. PMID: 30615550, PMCID: PMC7554677, DOI: 10.1200/jco.18.00690.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsFemaleHematopoietic Stem Cell TransplantationHumansLymphoma, Mantle-CellMaleMiddle AgedNorth AmericaProgression-Free SurvivalRetrospective StudiesRisk AssessmentRisk FactorsRituximabTime FactorsTransplantation, AutologousYoung AdultConceptsImproved progression-free survivalProgression-free survivalMantle cell lymphomaTransplantation-eligible patientsOverall survivalMultivariable regression analysisRituximab eraCell lymphomaLarge cohortMedian progression-free survivalPropensity score-weighted analysisAdults age 65 yearsImproved overall survivalAge 65 yearsB-cell lymphomaRegression analysisCyclin D1 expressionEligible patientsFit patientsImproved OSInduction chemotherapyYounger patientsSurvival outcomesUnadjusted analysesInclusion criteria